AR099083A1 - Compuesto de indol - Google Patents

Compuesto de indol

Info

Publication number
AR099083A1
AR099083A1 ARP150100079A ARP150100079A AR099083A1 AR 099083 A1 AR099083 A1 AR 099083A1 AR P150100079 A ARP150100079 A AR P150100079A AR P150100079 A ARP150100079 A AR P150100079A AR 099083 A1 AR099083 A1 AR 099083A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halogen
bond
substituted
Prior art date
Application number
ARP150100079A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR099083A1 publication Critical patent/AR099083A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

El compuesto de indol de la presente solicitud puede usarse como un agente para tratar y/o prevenir la incontinencia urinaria, en particular la incontinencia urinaria de esfuerzo y un tipo mixto de incontinencia urinaria, actuando como un agonista periférico de los receptores MT₁ y/o MT₂. Reivindicación 1: Un compuesto de la fórmula (1) o una sal del mismo, en la fórmula: R¹ es H o alquilo C₁₋₆; X es un enlace, -NH-, o -N(alquilo C₁₋₆)-; R² es alquilo C₁₋₆ que puede estar sustituido con 1 a 3 halógenos; Y es un enlace u -O-; R³ es un heteroarilo de 5 a 6 miembros que tiene al menos un heteroátomo seleccionado del grupo formado por O, S y N, siempre que cuando Y es un enlace, el heteroarilo es un heteroarilo de 5 miembros que tiene al menos dos heteroátomos seleccionados del grupo formado por O, S y N, y el heteroarilo puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo formado por alquilo C₁₋₆ que puede estar sustituido con 1 a 3 sustituyentes seleccionados del grupo formado por -OH, -O-(alquilo C₁₋₆), y halógeno; -O-(alquilo C₁₋₆); cicloalquilo C₃₋₈; y halógeno, y además, cuando Y es un enlace, R³ puede ser -NR³¹-CO-O-R³², R³¹ es H o alquilo C₁₋₆, R³² es alquilo C₁₋₆; R⁴ es H o halógeno; los R⁵ son iguales o diferentes entre sí, y son H o alquilo C₁₋₆; y los R⁶ son iguales o diferentes entre si, y son H o alquilo C₁₋₆.
ARP150100079A 2014-01-14 2015-01-13 Compuesto de indol AR099083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014004560 2014-01-14

Publications (1)

Publication Number Publication Date
AR099083A1 true AR099083A1 (es) 2016-06-29

Family

ID=53542928

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100079A AR099083A1 (es) 2014-01-14 2015-01-13 Compuesto de indol

Country Status (15)

Country Link
US (1) US9637451B2 (es)
EP (1) EP3095781B1 (es)
JP (1) JP6428645B2 (es)
KR (1) KR20160100998A (es)
CN (1) CN105916840B (es)
AR (1) AR099083A1 (es)
CA (1) CA2934825A1 (es)
ES (1) ES2694049T3 (es)
MX (1) MX2016009180A (es)
PL (1) PL3095781T3 (es)
PT (1) PT3095781T (es)
RU (1) RU2016133277A (es)
TR (1) TR201815422T4 (es)
TW (1) TW201617333A (es)
WO (1) WO2015108039A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4021574A4 (en) * 2019-08-28 2023-10-04 The Regents of the University of California BIORHYTHM MODULATORS AND THEIR USES
CN116496251A (zh) * 2023-04-25 2023-07-28 浙江理工大学 一种1h-吲哚-2-酰胺化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032871A1 (en) 1996-03-08 1997-09-12 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
FR2814165B1 (fr) 2000-09-15 2002-11-22 Adir Nouveaux derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
FR2907451B1 (fr) 2006-10-18 2008-12-12 Servier Lab "nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
US20150368220A1 (en) 2012-07-10 2015-12-24 Astellas Pharma Inc. Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical composition
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN103755686B (zh) * 2014-01-23 2016-05-11 中国药科大学 具有抗血小板聚集活性的哌啶基取代5-羟色氨酸衍生物

Also Published As

Publication number Publication date
RU2016133277A (ru) 2018-02-19
US20160332966A1 (en) 2016-11-17
PT3095781T (pt) 2018-11-16
RU2016133277A3 (es) 2018-08-07
MX2016009180A (es) 2016-10-05
CN105916840B (zh) 2019-01-08
JPWO2015108039A1 (ja) 2017-03-23
TW201617333A (zh) 2016-05-16
JP6428645B2 (ja) 2018-11-28
EP3095781B1 (en) 2018-10-03
WO2015108039A1 (ja) 2015-07-23
PL3095781T3 (pl) 2019-01-31
US9637451B2 (en) 2017-05-02
ES2694049T3 (es) 2018-12-17
EP3095781A1 (en) 2016-11-23
KR20160100998A (ko) 2016-08-24
CN105916840A (zh) 2016-08-31
TR201815422T4 (tr) 2018-11-21
EP3095781A4 (en) 2017-05-17
CA2934825A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
AR106041A1 (es) Moduladores de la proteína core de la hepatitis b
CL2018000697A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
CL2018000696A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
AR096339A1 (es) Agonistas del receptor de somatostatina subtipo 4 (sstr4)
AR100171A1 (es) Compuestos de diaminotriazina y su uso como herbicida
CO2019010804A2 (es) Derivados de indol n–sustituidos
AR097866A1 (es) Derivados de 4-azaindol
AR102258A1 (es) Compuestos de quinolina y quinazolina
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
UY36257A (es) “compuestos de imidazopiridazina”.
AR097138A1 (es) Compuestos plaguicidas
AR104293A1 (es) Indazolonas como moduladores de la señalización de tnf
AR118193A1 (es) Derivados de heterociclos bicíclicos fusionados como pesticidas
AR101798A1 (es) Quinolinas herbicidas
PE20170675A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
ECSP16096831A (es) Derivados de naftiridinadiona

Legal Events

Date Code Title Description
FB Suspension of granting procedure